Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium

被引:5
作者
Gerlier, Laetitia [1 ]
Lamotte, Mark [1 ]
Mendes, Sofia Dos Santos [2 ]
Damm, Oliver [3 ]
Schwehm, Markus [4 ]
Eichner, Martin [5 ,6 ]
机构
[1] IMS Hlth Real World Evidence Solut, Davos Bldg,Vincilaan 7, B-1935 Zaventem, Belgium
[2] SA AstraZeneca NV, Uccle, Belgium
[3] Univ Bielefeld, Bielefeld, Germany
[4] ExploSYS GmbH, Leinfelden Echterdingen, Germany
[5] Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Tubingen, Germany
[6] Epimos GmbH, Dusslingen, Germany
关键词
COST-EFFECTIVENESS; YOUNG-CHILDREN; ECONOMIC BURDEN; UNITED-STATES; EFFICACY; ENGLAND; GERMANY; FRANCE; TIME; METAANALYSIS;
D O I
10.1007/s40272-016-0180-6
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objectives Our objectives were to estimate the public health outcomes of vaccinating Belgian children using an intranasal tetravalent live-attenuated influenza vaccine (QLAIV) combined with current coverage of high-risk/elderly individuals using the trivalent inactivated vaccine. Methods We used a deterministic, age-structured, dynamic model to simulate seasonal influenza transmission in the Belgian population under the current coverage or after extending vaccination with QLAIV to healthy children aged 2-17 years. Differential equations describe demographic changes, exposure to infectious individuals, infection recovery, and immunity dynamics. The basic reproduction number (R-0) was calibrated to the observed number of influenza doctor visits/year. Vaccine efficacy was 80 % (live-attenuated) and 59-68 % (inactivated). The 10-year incidence of symptomatic influenza was calculated with different coverage scenarios (add-on to current coverage). Results Model calibration yielded R-0 = 1.1. QLAIV coverage of 75 % of those aged 2-17 years averted 374,000 symptomatic cases/year (57 % of the current number), 244,000 of which were among adults (indirect effect). Vaccinating 75 % of those aged 2-11 years and 50 % of those aged 12-17 years averted 333,200 cases/year (213,000 adult cases/year). Vaccinating only healthy children aged 2-5 years generated direct protection but limited indirect protection, even with 90 % coverage (40,800 averted adult cases/year; -8.4 %). Targeting all children averted twice as many high-risk cases as targeting high-risk children only (8485 vs. 4965/year with 75 % coverage). Sensitivity analyses showed the robustness of results. Conclusions The model highlights the direct and indirect protection benefits when vaccinating healthy children with QLAIV in Belgium. Policies targeting only high-risk individuals or the youngest provide limited herd protection, as school-age children are important influenza vectors in the community.
引用
收藏
页码:303 / 318
页数:16
相关论文
共 24 条
  • [21] Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
    Zhu, Fengcai
    Zhuang, Chunlan
    Chu, Kai
    Zhang, Liang
    Zhao, Hui
    Huang, Shoujie
    Su, Yingying
    Lin, Hongyan
    Yang, Changlin
    Jiang, Hanmin
    Zang, Xia
    Liu, Donglin
    Pan, Hongxing
    Hu, Yuemei
    Liu, Xiaohui
    Chen, Qi
    Song, Qiaoqiao
    Quan, Jiali
    Huang, Zehong
    Zhong, Guohua
    Chen, Junyu
    Han, Jinle
    Sun, Hong
    Cui, Lunbiao
    Li, Jingxin
    Chen, Yixin
    Zhang, Tianying
    Ye, Xiangzhong
    Li, Changgui
    Wu, Ting
    Zhang, Jun
    Xia, Ning-Shao
    LANCET RESPIRATORY MEDICINE, 2022, 10 (08) : 749 - 760
  • [22] Evaluation of tumorigenic potential of high yielding cloned MDCK cells for live-attenuated influenza vaccine using in vitro growth characteristics, metastatic gene expression and in vivo nude mice model
    Vepachedu, Ramarao S.
    Menon, Amritha
    Hussain, Althaf I.
    Liu, Jonathan
    BIOLOGICALS, 2012, 40 (06) : 482 - 494
  • [23] Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic
    Rubin, Jaime L.
    McGarry, Lisa J.
    Klugman, Keith P.
    Strutton, David R.
    Gilmore, Kristen E.
    Weinstein, Milton C.
    BMC INFECTIOUS DISEASES, 2010, 10
  • [24] Cost-effectiveness and public health impact of using high dose influenza vaccine in the Japanese older adults
    de Courville, Caroline
    Tadera, Chiho
    Arashiro, Takeshi
    Bianic, Florence
    Costa, Mafalda
    Joshi, Mohit
    Wang, Xinyu
    JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) : 544 - 555